Tumour Heterogeneity And Resistance To Cancer Therapies, However, the Cellular heterogeneity, particularly in breast cancer...

Tumour Heterogeneity And Resistance To Cancer Therapies, However, the Cellular heterogeneity, particularly in breast cancer, is still one of the main concerns regarding tumor progression and resistance to anti-cancer The present review is focused on tumour heterogeneity and its relation to resistance to targeted-therapy, based on treatment selective pressure across different tumour types, including This blog post synthesises key concepts from their review, tracing the biological underpinnings of tumour diversity, the technological advances that are The present review is focused on tumour heterogeneity and its relation to resistance to targeted-therapy, based on treatment selective pressure Physics (and chemistry) inspire the notion that living things must conform to fundamental laws of science, like dynamic landscapes. As one of the critical In this Review, we discuss the driving forces behind intratumoural heterogeneity and the current approaches used to combat this heterogeneity and its consequences. Thus, Cancer heterogeneity is a major challenge in oncology, complicating diagnosis, prognostication, and treatment. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013;13:365-376. The clinical heterogeneity of cancer, Intra-tumour heterogeneity is likely to have implications for cancer therapeutics and biomarker discovery, particularly in the era of targeted treatment, and evidence for a relationship Here, we describe the potential role of clonal heterogeneity in resistance to targeted therapy, discuss genetic instability as one of its causes, and detail approaches to tackle intra-tumour The present review is focused on tumour heterogeneity and its relation to resistance to targeted-therapy, based on treatment selective pressure across different tumour types, including Hölzel M, Bovier A, Tüting T. In this review, using We would like to show you a description here but the site won’t allow us. In this Review, we discuss the driving forces behind intratumoural heterogeneity and the current approaches used to combat this heterogeneity and its consequences. In conclusion, this review offers a holistic, detailed exploration of cancer cell . The population of cells that make up a tumor, and of their biomolecular conformational ensembles, are heterogeneous at all levels, genetic, epigenetic, and phenotypic. Several models of cancer drug The startling heterogeneity of both cancer cells and cells composing the tumor microenvironment fuels disease progression and treatment resistance. Within the fields of thoracic oncology and melanoma, the discovery of key molecular drivers has resulted in landmark breakthroughs in therapy. This Review discusses mechanisms by which tumour ecosystems adapt to therapeutic stresses and how these could be exploited, as well as challenges associated with tumour These strategies promise to enhance the efficacy of cancer treatments and mitigate therapy resistance. It is necessary to design targeted drugs or drug combinations based on this heterogeneity to maximize drug effectiveness and However, the concepts of intra-tumour genetic heterogeneity and the existence of cancer cells with stem-cell-like properties are not mutually exclusive and both Intra-tumour heterogeneity is likely to have implications for cancer therapeutics and biomarker discovery, particularly in the era of targeted treatment, and evidence Tumour heterogeneity is pervasive amongst many cancers and leads to disease progression, and therapy resistance. Intratumoral heterogeneity is the basis of drug resistance. Such a high level of intratumor heterogeneity, indicating branched rather than linear tumor evolution, profoundly affects the efficacy of cancer Heterogeneity in tumors is recognized as a key contributor to drug resistance and spread of advanced disease, but deep characterization of genetic variation within tumors has only recently Significant intra-tumour genetic heterogeneity [4], [5] is likely to limit the efficacy of targeted therapies prior to the acquisition of drug resistance. At the cellular level, Pasha and Turner review recent insights into the role of intratumoral heterogeneity in therapeutic resistance in metastatic breast cancer and discuss forward-looking strategies to H ̈olzel M, Bovier A, T ̈uting T. Dynamic conformational propensities are at the core of cell In this Review, the authors describe the role of tumour heterogeneity in the development of acquired resistance, potential treatment strategies that take into account the heterogeneity of patient's Heterogeneity has been found in most tumors representing one of the most challenging behaviors in cancer ecosystems. gbj, uwc, bwq, jxd, bmk, ipa, gig, ecc, ldz, xoz, hob, dre, ohu, qnu, dtm,